Live Feeds
● LIVE Updated 2h ago · 10 sources tracked

Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data

Foghorn Therapeutics is cutting 40% of its workforce, reducing staff to approximately 65 employees, after its cancer drug development collaboration with Eli Lilly collapsed. The partnership termination follows disappointing phase 1 dose-escalation data for FHD-909, also known as LY4050784, which failed to show sufficient efficacy to advance into an expansion phase. Additionally, the companies decided to scrap work on a related selective SMARCA2 degrader and chose not to extend their 2021 partnership. Foghorn stated that this restructuring and pipeline reprioritization will extend its cash runway into the second half of 2029.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (10)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Foghorn Therapeutics is laying off 40% of its workforce, leaving roughly 65 employees.
  • ✓ The collaboration between Foghorn and Eli Lilly ended after experimental cancer drug FHD-909 failed to show enough benefit in an early-stage phase 1 trial.
  • ✓ The companies are discontinuing work on both FHD-909, also called LY4050784, and a related selective SMARCA2 degrader.
  • ✓ TD Cowen cut Foghorn Therapeutics stock rating to Hold following the trial halt.
🛡️ Source Corroboration: 10 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Foghorn discontinued the experimental cancer drug partnered with Eli Lilly and announced a 40% workforce reduction on October 1, 2026.

Live updates

  1. Foghorn Lays Off 40% of Staff as Eli Lilly Cancer Partnership Fails

    Foghorn Therapeutics is cutting 40% of its workforce, reducing staff to approximately 65 employees, after its cancer drug development collaboration with Eli Lilly collapsed. The partnership termination follows disappointing phase 1 dose-escalation data for FHD-909, also known as LY4050784, which failed to show sufficient efficacy to advance into an expansion phase. Additionally, the companies decided to scrap work on a related selective SMARCA2 degrader and chose not to extend their 2021 partnership. Foghorn stated that this restructuring and pipeline reprioritization will extend its cash runway into the second half of 2029.

    Why it matters

    The partnership between Foghorn Therapeutics and Eli Lilly began in 2021 to develop and commercialize oncology products centering on experimental SMARCA2 inhibitors. Following the failure of the trial data to meet expectations, TD Cowen downgraded Foghorn stock rating to Hold, and shares dropped amid trader focus on the company's remaining cash runway and charts. Foghorn now plans to refocus entirely on its proprietary portfolio programs.

    What is confirmed

    • Foghorn Therapeutics is laying off 40% of its workforce, leaving roughly 65 employees.
    • The collaboration between Foghorn and Eli Lilly ended after experimental cancer drug FHD-909 failed to show enough benefit in an early-stage phase 1 trial.
    • The companies are discontinuing work on both FHD-909, also called LY4050784, and a related selective SMARCA2 degrader.
    • TD Cowen cut Foghorn Therapeutics stock rating to Hold following the trial halt.
    • Foghorn stated the restructuring and pipeline reprioritization will extend its cash runway into the second half of 2029.

    What to watch next

    • Performance and clinical progress of Foghorn's remaining proprietary portfolio programs
    • Future updates on Foghorn's cash runway and financial health following the restructuring
    Sources used for this update (11)
    1. Fierce Biotech — Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
    2. GlobeNewswire — Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
    3. Barron's — Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
    4. StocksToTrade — FHTX Stock Slides As Traders Focus On Cash Runway And Charts
    5. Investing.com — Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt
    6. www.biotech-now.co.uk — Foghorn lays off 40% of employees as Lilly cancer collab ...
    7. www.biospace.com — Foghorn lays off 40% of staff after Lilly collaboration ends
    8. theclinicaltimes.com — Foghorn cuts 40% of workforce after Lilly collaboration ends
    9. finance.yahoo.com — Foghorn to cut 40% of workforce after scrapping Lilly ...
    10. finance.yahoo.com — Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
    11. www.talk.bio — Foghorn cuts 40% of staff after ending Lilly cancer programs
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community